The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal ...
The announcement comes on the heels of a deal with the Trump administration to expand access to weight-loss drugs and reduce ...
Stenoparib, targeting PARP1/2 and tankyrase 1/2, offers a unique mechanism for treating advanced ovarian cancer. The FDA's fast track designation facilitates expedited development and review, with ...
In preclinical prostate cancer models, HLD-0915 treatment resulted in tumor shrinkage and declines in prostate-specific antigen. The Food and Drug Administration (FDA) has granted Fast Track ...